"Evidence based" evaluation of treatment in ADHD. Attention deficit hyperactivity disorder (ADHD) is marked by limitations in diagnostic accuracy, psychobiological characterisation and assessment of treatment efficacy. A national consortium of scientists and clinicians is planning to address these issues using an assessment protocol recently developed by the Brain Resource Company Ltd, which involves integrated neuroscientific and psychometric measurement that taps many of the brain's informati ...."Evidence based" evaluation of treatment in ADHD. Attention deficit hyperactivity disorder (ADHD) is marked by limitations in diagnostic accuracy, psychobiological characterisation and assessment of treatment efficacy. A national consortium of scientists and clinicians is planning to address these issues using an assessment protocol recently developed by the Brain Resource Company Ltd, which involves integrated neuroscientific and psychometric measurement that taps many of the brain's information processing networks. Specifically, the aims of the project are to identify biological and cognitive markers that reflect ADHD in its untreated form, and markers that discriminate treatment effects relative to the pre treatment profile. The results from this study will be translated into a product that uses the protocol to provide a service able to profile ADHD more accurately and evaluate the effects of treatment.Read moreRead less
Proteomic analysis of central nervous system inflammation in multiple sclerosis. This project aims to identify new therapeutic targets and diagnostics for Multiple Sclerosis (MS) the most common neurological disease in young adults. The estimated economic burden of this disease in Australia is around $2 billion per annum. There is also a large social cost to take into account. In spite of a great deal of research, current therapies are limited. We expect that this this research will: lead to n ....Proteomic analysis of central nervous system inflammation in multiple sclerosis. This project aims to identify new therapeutic targets and diagnostics for Multiple Sclerosis (MS) the most common neurological disease in young adults. The estimated economic burden of this disease in Australia is around $2 billion per annum. There is also a large social cost to take into account. In spite of a great deal of research, current therapies are limited. We expect that this this research will: lead to new therapies and better diagnostics, which will reduce the financial and human cost of this disease; generate IP with subsequent economic benefits and; expand proteomics technologies which will have flow on effects including economic benefits and benefits to a wide range of basic research. Read moreRead less